Register
Register
Register

Annelies Bogaerts

Chief Development Officer

Benno Therapeutics

Leuven, Belgium

SpeakerSpeaker

My organisation

Benno Therapeutics

Benno Therapeutics

Biotech company/R&D

Leuven, Belgium

Benno Tx is developing an innovative immunotherapy targeting the tumor vasculature. Its vaccine against extracellular vimentin showed promising results in a phase 1/2 study, doubling survival in dogs with urothelial carcinoma (374 vs. 196 days, p<0.01) compared to chemotherapy. The IM-administered vaccine is safe, effective, and easy for general practitioners to use. This platform technology is expanding to other cancer types such as osteosarcoma and is expandable to other species, offering a scalable, affordable, and resistance-preventing cancer treatment. With strong PoC data, Benno Tx is advancing veterinary oncology with a first-in-class, targeted immunotherapy that has the potential to revolutionize cancer treatment in pets.
Read more

About me

Annelies holds a PhD in Biology from the Catholic University of Leuven and received the award for best Master Thesis in 2006. She has over 10 years of experience in biotech and life sciences, more specifically in developing regenerative medicine solutions for Animal Health applications. By leading the product development from idea to the clinic, Annelies has gained expertise in multiple areas. From R&D over regulatory through designing successful (pre)clinical studies and maintaining a strong, supportive KOL network. Annelies currently acts as Chief Development Officer at Benno Therapeutics, that develops innovative cancer treatments for pets and has an active role at Fishway, a seafood technology company that aims at producing safe, healthy and sustainable fish ingredients based on cellular aquaculture. Furthermore, Annelies is appointed as academic advisor at the Faculty of Veterinary Medicine of the University of Ghent.